Alcon will roll out the medication in Finland and Norway shortly. US sales since launch are in line with the Company's expectations. We look forward to further launches across the Nordic area and other countries to make sure that patients are able to get access to the first pharmacological treatment for VMT including when connected with a macular hole of size less than or equal to 400 microns Click to read more about the treatment . It really is administered through a single intravitreal injection to treat adults with vitreomacular traction . VMT, which in the US is referred to as symptomatic VMA, is an age-related progressive, sight-threatening condition.
Alere Determine HIV-1/2 Ag/Ab Combo check receives CLIA Waiver from FDA Alere Inc. , a global leader in quick diagnostic tests, today announced that the U.S. Until now, the check offers been available for purchase in the usa to health facilities and laboratories licensed to conduct tests of moderate complexity. With this approval, the test will today be accessible for use in physician offices, clinics and other general public health settings as well. Alere Determine HIV 1-2 Ag/Ab Combo was FDA-approved in August 2013 as the first fourth-generation, rapid point-of-care test that detects both HIV-1/2 antibodies and free HIV-1 p24 antigen.